Shares of Health Care sector company Summit Therapeutics moved 6.3% today, and are now trading at a price of $18.33. The Large-Cap stock's daily volume was 3,323,983 compared to its average volume of 3,875,657. The S&P 500 index returned a 0.0% performance.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. The company is based in Miami and has 159 full time employees. Its market capitalization is $13,645,632,512.
13 analysts are following Summit Therapeutics and have set target prices ranging from $12.101834 to $42.586708 per share. On average, they have given the company a rating of buy. At today's prices, SMMT is trading -43.4% away from its average analyst target price of $32.38 per share.
Over the last year, SMMT shares have gone down by -2.0%, which represents a difference of -14.2% when compared to the S&P 500. The stock's 52 week high is $36.91 per share and its 52 week low is $15.55. Summit Therapeutics has averaged free cash flows of $-69671166.7 over the last 5 years, with a mean growth rate of -32.2%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -142,106 | 139 | -142,245 | -85.0 |
| 2023 | -76,760 | 128 | -76,888 | -82.17 |
| 2022 | -41,582 | 624 | -42,206 | 42.1 |
| 2021 | -72,587 | 306 | -72,893 | -50.2 |
| 2020 | -48,111 | 421 | -48,532 | -37.63 |
| 2019 | -35,106 | 157 | -35,263 |
